Granisetron
Antiemetic & Gastroprokinetic · 5HT3-antagonist
Indications
Prevention of cytostatic or radiotherapy induced nausea and vomiting, prevention of post-operative nausea and vomiting. Treatment of post-operative nausea and vomiting.
Dosage
ORAL: Adults: 1 mg twice daily or 2 mg once daily, initial dose administered one hr prior to cytostatic therapy. Children: Not recommended. INFUSION: Cytostatic induced nausea and vomiting: Adults: Usually 3 mg diluted in 20-50 mL infusion fluid administered by IV infusion over 5 min or diluted in 15 mL infusion fluid administered by IV bolus Inj over 30 sec. If necessary repeat at intervals of at least 10 min; max 9 mg in 24 hr. Children: 40 mcg/kg (upto 3 mg) diluted in 10-30 mL infusion fluid administered by IV infusion over 5 min. If necessary repeat once within 24 hr at least 10 min after initial infusion. Prevention of post-operative nausea and vomiting: Adults: 1 mg diluted to 5 mL administered by slow IV injection over 30 sec prior to induction of anaesthesia. Treatment of post-operative nausea and vomiting: Adults: IV 1 mg, dose to be diluted to 5 mL and administered over 30…
Administration
IV: Administer as rapid (30 second) IV push or a short (5-10 min) infusion. For prevention of PONV, administer before induction of anaesthesia or before reversal of anaesthesia. For PONV, administer undiluted over 30 seconds. Compatibility: Stable in D5 ½ NS, D5NS, D5W, NS, bacteriostatic water. Incompatible with amphotericin (Y-site administration). Stability: Store at 25°C-30°C. Do not freeze vials. Protect from light. Stable when mixed in NS or D5W for 7 days under refrigeration and for 3 days at room temperature.
Adverse Effects
Headache, insomnia, GI upset, constipation, asthaenia, pain. Transient rise in liver enzymes. Reports of serotonin syndrome.
Risk Factor (Pregnancy/Lactation)
Pregnancy: Risk cannot be ruled out. Lactation: Contraindicated or not recommended. Precautions: Subacute intestinal obstruction. Cardiac disease, cardiotoxic chemotherapy, electrolyte abnormalities. Hepatic or renal impairment.
Interactions
CYP1A1 or CYP3A4 inhibitors or inducers. Other serotonergic drugs. Drugs that prolong QT interval.
Advice to Patient
Take tablets without meals. Patients wearing granisetron patch should cover it with cloth if there is a risk of exposure to sunlight. After removal of patch, continue covering application site for 10 days. Contact prescriber if there is constipation, fever, severe diarrhoea or severe headache.
Pharmacokinetics
Onset of action: IV: 1-3 min. Duration: Oral, IV: Up to 24 hrs. Subcutaneous (extended-release): Remains detectable in the plasma for 7 days. Absorption: Oral: Tab and oral soln are bioequivalent. Transdermal patch: Approx. 66% over 7 days. Metabolism: Hepatic. Half-life elimination: Oral: 6 hrs. IV: Mean range: 5-9 hrs. Subcutaneous (extended-release): Approx. 24 hrs. Time to peak, plasma: Transdermal patch: Max systemic conc: Approx. 48 hrs after application. Subcutaneous (extended-release): Approx. 24 hrs. Excretion: Urine, faeces.
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.